| Literature DB >> 30895265 |
N E van Hoogenhuijze1, J C Kasius2, F J M Broekmans1, J Bosteels3, H L Torrance1.
Abstract
STUDY QUESTION: What is the effect of endometrial scratching in patients with or without prior failed ART cycles on live birth (LBR) and clinical pregnancy rates (CPR)? SUMMARY ANSWER: It remains unclear if endometrial scratching improves the chance of pregnancy and, if so, for whom. WHAT IS KNOWN ALREADY: Endometrial scratching is hypothesized to improve embryo implantation in ART. Multiple studies have been published, but it remains unclear if endometrial scratching actually improves pregnancy rates and, if so, for which patients. STUDY DESIGN SIZE DURATION: For this review, a systematic search for published articles on endometrial scratching and ART was performed on 12 February 2018, in Pubmed, Embase and the Cochrane Library. PARTICIPANTS/MATERIALS SETTINGEntities:
Keywords: ART; ICSI; IVF; embryo implantation; endometrial injury; endometrial scratching; implantation failure
Year: 2019 PMID: 30895265 PMCID: PMC6396643 DOI: 10.1093/hropen/hoy025
Source DB: PubMed Journal: Hum Reprod Open ISSN: 2399-3529
Exact copy of the query used for each database search: the keywords were ‘IVF’ and ‘endometrial scratching’ and synonyms.
| Database | Search query |
|---|---|
| PUBMED | (IVF [Title/Abstract] OR ( |
| EMBASE | 'ivf’:ab,ti OR ‘in vitro fertilization’:ab,ti OR ‘implantation’:ab,ti OR ‘icsi’:ab,ti OR ‘intracytoplasmic sperm injection’:ab,ti OR ‘embryo’:ab,ti OR ‘assisted reproduction’:ab,ti OR ‘assisted reproductive’:ab,ti AND (‘endometrium’:ab,ti OR ‘endometrial’:ab,ti OR ‘pipelle’:ab,ti OR ‘novak’:ab,ti) AND (‘injury’:ab,ti OR ‘scratching’:ab,ti OR ‘scratch’:ab,ti OR ‘biopsy’:ab,ti OR ‘disruption’:ab,ti) |
| Cochrane | (‘IVF’:ti,ab,kw OR ‘ |
| ClinicalTrials.gov | (IVF OR implantation OR ICSI OR embryo OR ‘assisted reproduction’ OR ‘assisted reproductive’) AND (endometrium OR endometrial OR pipelle OR novak) AND (injury OR scratching OR scratch OR biopsy OR disruption) |
Figure 1Flowchart of the systematic literature search. Search date: 12 February 2018. n, number of records; RCT, randomized controlled trials; OS, ovarian stimulation; Group 0, no prior IVF/ICSI treatment; Group 1, one failed IVF/ICSI treatment; Group 2, two or more failed IVF/ICSI treatments.
Risk of bias summary for the randomized controlled studies.
The chart presents the authors’ judgment of each risk of bias item of each included study.
+, low risk of bias;?, uncertain risk of bias; −, high risk of bias.
Other bias: absence of power calculations, underpowered studies, or performance of procedures other than the studied intervention that could also lead to endometrial injury (i.e. hysteroscopy or sham). Note: Patients and personnel were usually not blinded for the intervention. Not blinding personnel could have led to adjusted embryo transfer techniques and was therefore regarded as ‘high risk’ for performance bias. On the other hand, outcome measures (live birth and clinical pregnancy rates) were unlikely to be influenced by unblinded personnel, so that all studies were regarded as ‘low risk’ for detection bias.
Study characteristics of each RCT included in the review.
| Study | Baum 2012 | Gibreel 2015 | Inal 2012 | Karimzadeh 2009 | Liu 2017 | Maged 2017 | Mahran 2016 |
|---|---|---|---|---|---|---|---|
| City, Country | Tel-Aviv, Israel | Mansoura, Egypt | Konya, Turkey | Yazd, Iran | Beijing, China | Giza, Egypt | Minia, Egypt |
| Patients | Intervention: | Intervention: | Intervention: | Intervention: | Intervention: | Intrvention: | Intervention: |
| Intervention/ Comparison | Intervention: Pipelle on CD 9–12 and 21–24 of the cycle preceding the IVF treatment cycle. Control: Cervical introduction Pipelle. | Intervention: Pipelle on CD21 of the cycle preceding the IVF treatment cycle + 2–3 days thereafter. Control: Sound through cervix up to internal os. Note: HY in case of difficulty passing the cervical os. | Intervention: Pipelle twice with 1-week interval during the luteal phase of the GnRH-analog down regulation cycle prior to the ICSI-ET. Antibiotics after procedure. Control: Usual care. | Intervention: Pipelle on CD21–26 of spontaneous menstrual cycle preceding the ART treatment cycle, when GnRh agonist use began. Control: Usual care. | Intervention: Pipelle on CD10-12 or Pipelle on LH + 7–9 days. Control: sham procedure: Pipelle inserted through the cervix without inducing endometrial injury. | Intervention: Pipelle once in midluteal phase of the cycle preceding the ICSI treatment cycle. Control: Usual care. | Intervention: Pipelle once between CD21–24 of the cycle preceding IVF stimulation cycle Control: Usual care All patients received HY at CD2-5 in the cycle preceding ICSI treatment. |
| In- and exclusion criteria | Inclusion: Age: 18–41. ≥3 failed IVF cycles. Good ovarian response in previous cycles. Exclusion: Uterine malformation. Endometrioma. Hydrosalpinx at US. | Inclusion: Age: <40. ≥1 failed IVF cycle. Exclusion: Poor ovarian response in previous cycles. Endocrinopathy. History of tubal disconnection for hydrosalpinx. History of endometrial curettage <3 months prior to the study. Fibroids, polyps or adhesions. | Inclusion: ≥1 failed IVF/ICSI cycle. Good ovarian response in previous cycles. Exclusion: Thrombophilia. Hydrosalpinx, or submucous myoma at US. Factors found to have a negative impact on implantation. | Inclusion: Age: 20–40. 2–6 failed ART cycles with the transfer of at least 10 high-grade embryos. No history of blood diseases. Exclusion: Poor responders. Uterine malformation. Endometrioma. Hydrosalpinx at US. | Inclusion: Age < 41 years. No history of prior IVF/ICSI treatment. Normal uterine cavity confirmed with SIS US, basal FSH < 12IU/l. Exclusion: hydrosalpinx, endometriosis, endometrial polyp/fibroid. | Inclusion: Age < 40 years. No history of prior IVF/ICSI treatment. Basal FSH < 10IU/l. >2 basal follicles on US. Normal uterine cavity (confirmed by HY or HSG). Exclusion: endocrine abnormalities, ovarian cysts, hydrosalpinx, endometrial polyps, partner with azoospermia, pre-implantation genetic diagnosis. | Inclusion: Age 20–40 years. No history of prior IVF/ICSI treatment. History of ≥2 good quality embryo’s transferred. Normal uterine cavity (confirmed with HY during workup). Exclusion: endometrial fibroid or polyp, Asherman’s syndrome, congenital uterine malformations. |
| Patient selection | Not described | Not described | Not described | Not described | Not described | Not described | Consecutive |
| Randomization | Table of random numbers | Computer-generated tables of random numbers | Computer-generated random numbers | Drawing a piece of paper from a bag containing equal number of printed paper for each method | Table of random numbers | Automated web-based randomization | Not described |
| Allocation concealment | Not described | Sealed envelopes | Not described | Not described | Not described | Not described | Sealed envelopes |
| Blinding | Single | Single | Not described | Not described | Not described | None | Not described |
| Loss to follow-up | None | None | None | None | |||
| Outcome measuresa | Implantation, clinical pregnancy (gestational sac with embryonic pool), live birth. | Clinical pregnancy (positive cardiac activity at GA 8 weeks), live birth, miscarriage (after confirmation of a clinical pregnancy), multiple pregnancy (no definition). | Implantation, clinical pregnancy (positive cardiac activity), ongoing pregnancy (GA > 12 weeks), | Chemical pregnancy, clinical pregnancy (positive cardiac activity). | Implantation, biochemical pregnancy, clinical pregnancy (intrauterine gestational sac on US at 6 weeks’ gestation), multiple pregnancy, miscarriage, | Clinical pregnancy (gestational sac and positive heartbeat on US at 6 weeks’ gestation), multiple pregnancy ( > 1 fetuses on US at 6 weeks’ gestation), miscarriage (spontaneous miscarriage < 12 weeks’ gestation). |
n, number of participants; CD, cycle day; ET, embryo transfer; GA, gestational age; HY, hysteroscopy; SIS, saline infusion sonography; TB, tuberculosis; US, ultrasound.
aIn bold the primary outcome measure if described.
Figure 2Live birth rate after the IVF/ICSI cycle following randomization. a Live birth rate for participants with no prior IVF/ICSI treatment (Group 0), and subgroup analysis. Events, live birth; M–H, Mantel–Haenszel. b Live birth rate for participants with one failed complete IVF/ICSI cycle (Group 1). Events, live birth; M–H, Mantel–Haenszel. None of the trials had a risk of unintentional endometrial injury in the control group. Thus, subgroup analysis was not performed. c Live birth rate for participants with two failed complete IVF/ICSI cycles (Group 2), and subgroup analysis. Events, live birth; M–H, Mantel–Haenszel.
Figure 3Clinical pregnancy rate after the IVF/ICSI cycle following randomization. a Clinical pregnancy rate for participants with no prior IVF/ICSI treatment (Group 0), and subgroup analysis. Events, clinical pregnancy; M–H, Mantel–Haenszel. b Clinical pregnancy rate for participants with one failed complete IVF/ICSI cycle (Group 1). Events, clinical pregnancy; M–H, Mantel–Haenszel. None of the trials had a risk of unintentional endometrial injury in the control group. Thus, subgroup analysis was not performed. c Clinical pregnancy rate for participants with two failed complete IVF/ICSI cycles (Group 2), and subgroup analysis. Events, clinical pregnancy; M–H, Mantel–Haenszel.
Figure 4Miscarriage rate for the overall population (Groups 0, 1 and 2 combined), and subgroup analysis. Events, miscarriage; M–H, Mantel–Haenszel.
Figure 5Multiple pregnancy rate for the overall population (Groups 0, 1 and 2 combined), and subgroup analysis. Events, multiple pregnancy; M–H, Mantel–Haenszel.